Biocryst Pharmaceuticals (BCRX) executive compensation, 2026 proxy

Jon P. Stonehouse, Former President and Chief Executive Officer, was paid $13M in 2025, up 56% from $8.3M the year before. The CEO-to-median-employee pay ratio was 41:1, on median employee pay of $314,234.

Filed
April 23, 2026
Annual meeting
June 11, 2026
Pay year
2025
Named executives
6
CEO total pay
$13M+56% vs prior year
CEO to median employee
41:1median $314,234
Prior say-on-pay support
95%of votes cast
Total Employees
435Excluding former CEO
Peer Group Size
18Peer companies

How Stonehouse was paid

$13M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary6%Option awards86%Non-equity incentive8%All other compensation0%

Named executive officers

ExecutiveTotal
Jon P. StonehouseFormer President and Chief Executive Officer$12,951,082
Anthony J. DoyleFormer Chief Financial Officer and Treasurer$2,141,135
Babar GhiasChief Financial Officer$6,748,152
Helen M. Thackray, M.D.Former Chief R&D Officer$4,339,624
Alane P. BarnesChief Legal Officer and Corporate Secretary$5,616,032
Charles K. GayerPresident and Chief Executive Officer; Former Chief Commercial Officer$9,627,868

What changed and why

  • $13MJon P. Stonehouse received a total compensation of $12,951,082 for fiscal year 2025.
  • 95%Stockholders approved the prior say-on-pay proposal with more than 95% of the votes cast.
  • Babar Ghias joined the company as Chief Financial Officer on July 7, 2025.
  • Charles K. Gayer transitioned to President and Chief Executive Officer during the fiscal year.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.